There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Jounce Therapeutics Inc (JNCE), Sangamo Biosciences (SGMO) and ProQR (PRQR) with bullish sentiments.
Jounce Therapeutics Inc (JNCE)
In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on Jounce Therapeutics Inc, with a price target of $13. The company’s shares closed yesterday at $5.57.
Chattopadhyay commented:
“Our 12-month target remains at $13, post 1Q19 corporate update, which is based on a 12-year DCF and limited to the prospects of vopra (JTX-2011), with potential upside from JTX-4014 and JTX-8064. Our DCF is driven by: beta of 1.2 terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 8.6%, and tax rate of 15% beginning in FY 2026.”
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 1.0% and a 45.1% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Autolus Therapeutics Plc, and Voyager Therapeutics Inc.
Currently, the analyst consensus on Jounce Therapeutics Inc is a Hold with an average price target of $13.
See today’s analyst top recommended stocks >>
Sangamo Biosciences (SGMO)
Cowen & Co. analyst Ritu Baral maintained a Buy rating on Sangamo Biosciences today. The company’s shares closed yesterday at $11.31.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 27.5% and a 52.1% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.
Currently, the analyst consensus on Sangamo Biosciences is a Moderate Buy with an average price target of $22.50.
ProQR (PRQR)
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on ProQR today and set a price target of $20. The company’s shares closed yesterday at $11.05.
Fein wrote:
“Our price target of $20/share is based on an equally-weighted composite of: (a) $20.6/share, as a 25x multiple of taxed and diluted $10.01 discounted back to FY19 at 32% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $19.6/ share (discounted cash flow analysis using a 21% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company).”
According to TipRanks.com, Fein is a 4-star analyst with an average return of 5.0% and a 42.2% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ProQR with a $28.33 average price target, representing a 156.4% upside. In a report released today, Chardan Capital also reiterated a Buy rating on the stock with a $25 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
